In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Relationship between left ventricular mechanical dyssynchrony and myocardial sympathetic innervation: the role of innervation/perfusion mismatch

Session Poster session 5

Speaker Riccardo Liga

Event : ESC Congress 2017

  • Topic : imaging
  • Sub-topic : Nuclear Imaging
  • Session type : Poster Session

Authors : R Liga (Pisa,IT), A Gimelli (Pisa,IT), F Menichetti (Pisa,IT), E Soldati (Pisa,IT), MG Bongiorni (Pisa,IT), P Marzullo (Pisa,IT)

R. Liga1 , A. Gimelli2 , F. Menichetti1 , E. Soldati1 , M.G. Bongiorni1 , P. Marzullo3 , 1Azienda Ospedaliero-Universitaria Pisana - Pisa - Italy , 2Fondazione G. Monasterio CNR – Regione Toscana - Pisa - Italy , 3CNR Institute of Clinical Physiology & Fondazione Toscana G. Monasterio - Pisa - Italy ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 896

Background: The existence of an association between left ventricular (LV) mechanical dyssynchrony and impaired myocardial adrenergic tone has been hypothesized. However, a comprehensive evaluation of the relationships between regional LV perfusion, adrenergic innervation and mechanics is still lacking.

Purpose: To assess the interactions between regional left ventricular (LV) sympathetic innervation, perfusion and mechanical dyssynchrony in patients submitted to low-dose nuclear imaging on a Cadmium-Zinc-Telluride (CZT) camera.

Methods: Eighty-three patients underwent a combined evaluation of LV perfusion and sympathetic innervation at 99mTc-tetrofosmin/123I-metaiodobenzylguanidine (123I-MIBG) CZT imaging. The summed rest score (SRS) and summed 123I-MIBG score (SS-MIBG) were computed as measures of LV perfusion and innervation heterogeneity. The extent of “innervation/perfusion” mismatch was computed as the number of denervated LV segments with relatively preserved perfusion. LV mechanical dyssynchrony (LVD) was evaluated at phase analysis on gated CZT images and the LV wall with the latest mechanical activation identified.

Results: LVD was revealed in 36 (43%) patients. Patients with LVD had lower LV ejection fraction (28±10% vs 54±15%, P<0.001) and more abnormal SRS (21±9 vs 10±8, P<0.001) and SS-MIBG (29±9 vs 17±11, P<0.001) values than those with normal mechanical activation. On a per-patient basis, the presence of LVD was associated with a higher burden of “innervation/perfusion” mismatch (8±4 vs 6±3 LV segments in patients without dyssynchrony, P=0.019).

At wall-based analysis, LV walls with delayed mechanical activation also showed a significantly higher burden of “innervation/perfusion” mismatch (2.3±1.4 segments) than normally contracting walls of patients with LVD (1.7±1.3 segments) and of subjects without LVD (1.3±1.2 segments; P<0.001).

At multivariate analysis, after correction for clinical, LV functional and perfusion variables, the extent of “innervation/perfusion” mismatch was the only predictor of LVD [Odds ratio (OR): 1.34, 95% confidence interval (CI): 1.06–1.67; P=0.012], together with LV ejection fraction [OR: 0.84, 95% CI: 0.77–0.91; P<0.001].

Conclusions: LVD clusters with alterations of regional myocardial perfusion and sympathetic innervation.

Patients with LVD show an elevated burden of “innervation/perfusion” mismatch that is concentrated at the level of the dyssynchronous walls.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are